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Caspase-3 Activity Predicts Local Recurrence in Rectal Cancer
Pieter de Heer,1Elza C. de Bruin,2 Elma Klein-Kranenbarg,1Remco I.J.M. Aalbers,1CorrieA.M.Marijnen,6
Hein Putter,3 HansJ. de Bont,5 J. Fred Nagelkerke,5 J. HanJ.M. van Krieken,7 Hein W. Verspaget,4
CornelisJ.H. van deVelde,1and Peter J.K. Kuppen,1 for the Dutch Colorectal Cancer Group
Abstract Purpose: Radiotherapy followedby totalmesorectal excision surgery has been shown to signifi-
cantly reduce local recurrence rates in rectal cancer patients. Radiotherapy, however, is associated
withconsiderablemorbidity.Thepresent studyevaluated theuseofbiochemicaldetectionofenzy-
matic caspase-3 activity aspreoperativemarker forapoptosis topreselectpatients that areunlikely
to develop a local recurrence to spare these patients from overtreatment and the negative side
effectsof radiotherapy.
Experimental Design: Nonirradiated freshly frozen tissue samples from117 stage III rectal
cancerpatientswerecollectedfromarandomizedclinicaltrialthatevaluatedpreoperativeradiotherapy
in totalmesorectal excision surgery. Additional frozen archival tissues from47 preoperative biopsies
andcorresponding resectedcolorectal tumorswere collected. Levelofapoptosiswas determinedby
measuringtheenzymaticactivityofcaspase-3 inabiochemicalassay.
Results: In tumor tissue, caspase-3 activity lower than themedianwas predictive of 5-year local
recurrence(hazard ratio,7.4;95%confidenceinterval,1.7-32.8;P =0.008),whichwasunaffectedby
adjustment for type of resection, tumor location, andTstatus (adjustedhazard ratio, 7.5; 95%confi-
dence interval, 1.7-34.1; P = 0.009). Caspase-3 activity in preoperative biopsies was significantly
correlatedwithcaspase-3activity incorrespondingresectedtumors (r =0.56;P <0.0001).
Conclusion: Detection of tumor apoptosis levels by measuring caspase-3 activity, for which a
preoperative biopsy can be used, accurately predicted local recurrence in rectal cancer patients.
These findings indicate that caspase-3 activity is an important denominator of local recurrence
and should be evaluated prospectively to be added to the criteria to select rectal cancer patients
in which radiotherapy is redundant.
Local recurrence is a major problem after rectal cancer surgery,
as it is the cause of severely disabling symptoms and is difficult
to treat (1, 2). Local recurrence rates historically vary between
15% and 45% (3–5). The introduction of total mesorectal
excision (TME) as treatment for patients with rectal cancer has
led to an improved local control and survival when compared
with historical controls (2, 6, 7). In addition to improved
surgery, the administration of preoperative radiation therapy
has further decreased local recurrence rates in several random-
ized clinical trials (8–12). Radiation therapy, however, is
associated with considerable morbidity. Several studies have
evaluated the short-term and long-term morbidity of radiation
therapy. Preoperative radiation therapy is associated with fecal
incontinence, urgency, and anal blood loss (13). In addition to
the general bowel dysfunction, an increase in sexual dysfunc-
tion has been reported (14, 15). These negative side effects of
radiation therapy emphasize the need for finding predictive
factors for local recurrence to exclude patients with a very high
probability for cure with surgery alone.
Among the predictive factors for survival and local tumor
recurrence are lymph node metastasis, stage of the disease, and
the presence of a tumor-positive circumferential margin (12).
Most criteria, however, can only be determined postoperatively.
Several recent studies in rectal cancer have shown that tumors
with high levels of apoptosis show low local recurrence rates
and favorable prognosis (16–19). These results indicate that
only patients with low levels of apoptosis may benefit from
radiation therapy with respect to the development of local
recurrences. Therefore, the level of apoptosis in tumors may
provide a criterion to select patients for radiation therapy. The
present study evaluated the use of biochemical detection of
caspase-3 activity as a simple and quantitative technique to
measure apoptosis in tissue samples and preoperative biopsies
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of rectal cancer to predict local recurrences in rectal cancer. The
proapoptotic enzyme caspase-3 is activated at a point of
convergence for the intrinsic and extrinsic apoptosis induction
pathways (20), so its activity should give a reliable measure of
ongoing levels of apoptosis in tumor samples. The study was
done in stage III rectal cancer patients, as these are the patients
that are most likely to benefit from preoperative radiation
therapy (11, 12).
Materials andMethods
Patients. The study population consisted of two sources of
pathologic material.
The first consisted of stage III rectal cancer patients who participated
in the Dutch TME trial. These were collected and analyzed for caspase-3
activity to evaluate the prognostic value of caspase-3 activity. In the TME
study, patients were randomized to receive radiation therapy before
undergoing surgery according to a standardized TME protocol (12).
Patients were selected from the trial arm that did not receive
preoperative radiation therapy. All stage III patients who complied
with the eligibility criteria of the TME trial (12) and of whom frozen
tumor material was available were selected for this study, resulting in a
study cohort of 117 patients. Frozen tissue samples of adjacent normal
rectum tissue were available from 29 of the patients. A pathology review
committee reviewed all tumors (12). Any specimen that had tumor
(i.e., primary tumor or lymph node metastasis) V1 mm from the
circumferential margin was recorded as having a positive resection
margin (21).
The second source consisted of 47 frozen biopsies and
corresponding frozen rectal and rectosigmoidal, nonirradiated tumor
tissues. These were collected and analyzed for caspase-3 activity to
evaluate the feasibility of caspase-3 detection in biopsies and to assess
Table 1. Patient characteristics of the 117 included rectal cancer patients
Patient characteristic No. patients (%) Caspase-3 activity (pmol AMC/min/mg protein) P
N = 117 (100%) Median (IQR)
Gender 0.32
Male 81 (69) 14.5 (9.8-26.6)
Female 36 (31) 16.1 (13.1-27.2)
Age (median, 65; range, 26-85) 0.94
< Median 61 (52) 15.5 (5.8-26.5)
> Median 56 (48) 15.1 (5.2-27.2)
Preoperative CEA levels (median, 3.0; range, 2-41) 0.20
< Median 47 (40) 17.8 (12.2-30.4)
> Median 70 (60) 14.5 (9.5-23.6)
Maximum tumor diameter (median, 4.5; range, 0-11) 0.09
< Median 51 (44) 13.8 (9.3-22.7)
> Median 64 (56)* 16.2 (12.7-31.5)
Distance of tumor from anal verge (cm) 0.73
10.1-15 38 (33) 15.3 (11.6-26.4)
5.1-10 49 (42) 15.0 (9.7-24.8)
V5 30 (25) 16.3 (9.9-31.2)
Grade of differentiation 0.12
Well 4 (3) 13.7 (12.4-31.1)
Moderate 79 (68) 16.0 (12.0-29.8)
Poor 34 (29) 13.3 (5.8-20.2)
WHO classification 0.04
Adenocarcinoma 105 (90) 16.2 (10.4-28.6)
Mucinous carcinoma 12 (10) 12.8 (11.2-14.0)
No. positive lymph nodes 0.64
1-3 71 (61) 16.0 (10.1-29.8)
z4 46 (39) 14.2 (11.0-22.8)
T status 0.62
T1-T2 22 (19) 14.7 (8.5-27.9)
T3 89 (76) 16.2 (11.0-27.1)
T4 6 (5) 12.7 (9.9-22.7)
Circumferential margin 0.04
Negative 81 (69) 16.4 (11.8-30.1)
Positive 36 (31) 13.4 (9.5-17.6)
Type of resection 0.18
Abdominoperineal 40 (34) 17.4 (12.2-26.8)
Low anterior 77 (66) 14.5 (9.4-27.1)
Adjuvant therapy 0.37
None 83 16.2 (12.0-29.8)
Chemotherapy 6 16.2 (10.4-22.1)
Radiation therapy 24 13.1 (19.4-17.6)
Chemoradiation therapy 4 11.2 (6.1-55.6)
NOTE: Association of clinical and pathologic variables with caspase-3 activity as determined in Materials and Methods. Significant associations
are stated in bold.
Abbreviation: CEA, carcinoembryonic antigen.
*Tumor diameter of two tumors was not determined.
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whether caspase-3 activity in preoperative biopsies is representative
for that of the primary tumor. As preoperative biopsies were not
collected in the TME trial, biopsies and corresponding nonirradiated
tumor specimens were collected from the tissue archives of the Leiden
University Medical Center. As these patients did not receive TME
surgery and therefore have poor local control, they were not included
in survival analyses.
The study was conducted following the regulations according to
Dutch law for human material for research. Ethics board approval was
obtained for gathering all study material and patient data in the current
study.
Measurement of caspase-3 activity. The enzymatic activity of
caspase-3 in tissue samples was measured as described previously
(22). Briefly, five 10-Am cryostat sections of tumor or normal tissue
were suspended in a lysis buffer consisting of 10 mmol/L HEPES
(pH 7.0), 40 mmol/L h-glycerophosphate, 50 mmol/L NaCl, 2 mmol/L
MgCl2, and 5 mmol/L EGTA. After 10 min on ice, the cells were
disrupted by 10 s of sonification followed by four cycles of freezing
and thawing and stored at -80jC. Protein concentration was
determined using the method described by Bradford (23). For
measurement of caspase-3 enzymatic activity, samples containing
15 Ag protein were incubated with 2.5 nmol of the enzyme
substrates DEVD-AMC (Bachem) in a 100-mmol/L HEPES buffer
(pH 7.25) containing 10% (w/v) sucrose, 0.1% (v/v) NP40, and
10 mmol/L DTT. During incubation at 37jC, fluorescent AMC was
cleaved off by active caspases, corresponding with the level of caspase
activity in the sample. The fluorescent AMC was monitored at an
excitation of 360 nm and emission of 460 nm using a FLUOstar
Optima plate reader (BMG Labtech GmbH). Calibration curves were
constructed using free AMC. Caspase-3 activity was indicated in pmol
AMC/min/mg protein.
Tumor sections and preoperative biopsies may contain various
proportions of tumor epithelium and tumor stroma. To assess whether
caspase-3 activity depended on the ratio of tumor epithelium and
tumor stroma in sections of the tumor tissues used for analysis, the
percentage of tumor epithelium was assessed by two independent
observers (R.I.J.M.A. and N.G.E.) in adjacent H&E-stained slides.
Statistical analysis. Analysis was done with Statistical Package for
the Social Sciences statistical software (version 11.0 for Windows;
SPSS, Inc.). Mann-Whitney U , Kruskal-Wallis, Wilcoxon signed rank,
and Spearman’s Rho tests were used to compare continuous variables.
The entry date for the recurrence analyses was the time of surgery
of the primary tumor. To guarantee sufficient number of patients in
both groups, the patients were dichotomized at the median level of
apoptosis by caspase-3 activity. Kaplan-Meier analyses and log-rank
tests were done to compare recurrence rates in patients from the high
and low apoptotic groups. Cox regression analyses were used to
calculate hazard ratios with 95% confidence intervals for categorical
variables. Variables with a P value of V0.10 in the univariate analyses
were subjected to a multivariate analysis. To enable comparisons of
the outcome of caspase-3 data with recurrence rate of stage III rectal
cancer patients treated with radiation therapy, Kaplan-Meier analysis
was done for these patients in the follow-up data of the Dutch TME
trial (12).
Results
Level of apoptosis in rectal cancer. We determined caspase-3
activity in rectal cancer specimens and adjacent normal tissue in
a biochemical cleavage assay. Caspase-3 activity in the rectal
tumor specimens was significantly higher than in the 29
normal tissue samples: median, 15.2 pmol AMC/min/mg
protein; interquartile range (IQR), 10.6-26.9 compared with
median, 4.9 pmol AMC/min/mg protein; IQR, 3.4-10.5
(P < 0.0001, Wilcoxon signed rank). There was no significant
correlation between caspase-3 activity in tumor tissue and
adjacent normal tissue (correlation coefficient = 0.04; P = 0.85,
Spearman’s Rho test).
Correlation between clinical variables and apoptosis. The
characteristics of the stage III rectal cancer patients included in
this study are summarized in Table 1. Patient characteristics and
several markers that have an effect on disease recurrence in
rectal cancer, or that can be used as diagnostic tool (24–26),
were evaluated for their association with level of apoptosis
caspase-3 activity.
Fig. 1. Recurrence rates sinceTME surgery for low
(gray) and high (black, dotted) levels of apoptosis
in tumors of117 rectal cancer patients. Levels of
caspase-3 activity above the median were
associated with significantly lower local recurrence
rates (5-y risks: 5.9% versus 28.1%; P = 0.002,
log-rank analysis).
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Mucinous type of carcinoma and tumors with tumor-positive
circumferential margins were associated with lower caspase-3
activity (P = 0.04 and 0.04, respectively); all other variables
were not significant (Table 1).
Predictive value of caspase-3 activity for local recurrence. In
the current study, caspase-3 activity with the median as cutoff
point was accurately predictive for local tumor recurrence (P =
0.002, log-rank test; Fig. 1). After 5 years of follow-up, the local
recurrence rates were 28.1% in the tumors with caspase-3
activity below the median and 5.9% in tumors with caspase-3
activity above the median. Caspase-3 activity below the median
was also associated with high distant recurrence rates (69.0%
versus 42.2% in the group with high caspase-3 activity after
5 years; P = 0.05, log-rank test) but did not have an effect on
patient survival (P = 0.10, log-rank test).
To evaluate the benefit of short-term radiotherapy for the
above-described recurrence rates of low and high levels of
apoptosis, we calculated the 5-year local recurrence rate of all
stage III rectal cancer patients treated with preoperative radiation
therapy included in the Dutch TME trial (N = 243). Stage III
patients receivingpreoperative radiation therapyhad a 5-year local
recurrence rate of 11.4%. This percentage shows that patients with
high levels of apoptosis have sufficiently low recurrence rates
(5.9%) to make preoperative radiation therapy redundant.
Univariate and multivariate analysis. To assess the indepen-
dent predictive value of caspase-3 activity on local recurrences,
variables with a significant effect on local recurrence, shown in
Table 2, were analyzed in a multivariate analysis. Proximal
location of the tumor from the anal verge (P = 0.007),
abdominoperineal resection (P = 0.06), T status (P = 0.10), and
high caspase-3 activity (P = 0.008) proved to be associated with
low local recurrence rates in stage III rectal cancer and were
subjected to a multivariate analysis.
In the multivariate Cox regression analysis (Table 3), caspase-
3 levels below the median proved to be an independent
predictor of a high risk of local recurrence in stage III rectal
cancer (P = 0.009; hazard ratio, 7.5; 95% confidence interval,
1.7-34.1), whereas type of operation, T status, and distance
of tumor from anal verge had no independent prognostic value
with regard to this end point (Table 3).
If the circumferential margin (P = 0.13 in the univariate
analysis) was included in the multivariate analysis, caspase-3
levels below the median remained an independent predictor of
a low risk of local recurrence in stage III rectal cancer (P =
0.007; hazard ratio, 8.0; 95% confidence interval, 1.8-36.5).
Correction for percentage of tumor epithelium. Because the
cleavage assay used in the current study did not discriminate
between caspase-3 activity in tumor epithelium and tumor
stroma, we corrected the caspase-3 activity for the percentage
tumor epithelium to evaluate the influence variety in the
percentages of epithelium and stroma. Caspase-3 levels were
compared with levels corrected for percentage tumor epitheli-
um. Median caspase-3 levels before and after adjustment were
15.2 (IQR, 10.6-26.9) and 17.3 (IQR, 10.4-38.3) pmol AMC/
min/mg protein, respectively.
All statistical analyses in the current study were repeated
using caspase-3 levels adjusted for percentage tumor epithelium
in the frozen tissue sections. Results were unaffected whether
the original or adjusted levels were used, indicating that
caspase-3 activity can be assessed in tumor tissue specimens
without previous knowledge of the tumor epithelium to stroma
ratio in the tissue specimen.
Evaluation of possible selection bias. A total of 271 stage III
patients was included in the TME trial. To investigate whether
the patients in the current study were subject to a selection bias,
patient and tumor characteristics of the 117 included patients
were compared with all remaining eligible nonirradiated stage
III patients included in the TME trial (N = 154). No significant
differences in patient age (P = 0.80) and gender (P = 0.10) were
found. No differences in tumor characteristics as T stage
(P = 0.49), N stage (P = 0.30), grade of differentiation
(P = 0.22), localization (P = 0.72), WHO classification (P = 0.65),
carcinoembryonic antigen levels (P = 0.07), or circumferential
margins (P = 0.43) were found. The maximum tumor diameters
in the current study were significantly larger (5.0 cm versus
4.5 cm; P = 0.02) than in nonincluded tumors. This can be
explained by the fact that tumors with sufficient material for
study tended to be large specimens. As tumor size was not of
prognostic value in the current study, we concluded that
patients were not subject to a selection bias.
Table 2. Univariate Cox regression analysis of the
effect of clinical and pathologic variables on local
recurrence rates in stage III rectal cancer
Variable Association with
local recurrence
HR (95% CI) P
Age (y) 1.0 (0.98-1.03) 0.50
Preoperative CEA levels (ng/mL) 1.0 (0.98-1.03) 0.58
Maximum tumor diameter (cm) 0.91 (0.77-1.10) 0.26
Gender 0.24
Male 1
Female 0.73 (0.42-1.25)
Distance of tumor from anal verge (cm) 0.007
10.1-15 1
5.1-10 3.7 (1.6-8.7)
V5 2.3 (1.0-5.3)
Grade of differentiation 0.30
Well 1
Moderate 0.49 (0.2-1.2)
Poor 0.63 (0.2-1.7)
WHO classification 0.82
Adenocarcinoma 1
Mucinous carcinoma 1.1 (0.7-1.7)
No. positive lymph nodes 0.68
1-3 1
z4 1.1 (0.6-1.9)
T status 0.10
T1-T2 1
T3 2.6 (1.0-6.6)
T4 3.4 (0.9-12.5)
Circumferential margin 0.13
Negative 1
Positive 1.6 (0.9-2.7)
Caspase-3 activity 0.008
> Median 1
V Median 7.4 (1.7-32.8)
Type of resection 0.06
Abdominoperineal 1
Low anterior 1.7 (1.0-3.0)
Adjuvant therapy 0.24
No 1
Yes 1.9 (0.7-5.2)
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.
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Caspase-3 activity in preoperative biopsies and resected rectal
tumors. Finally, we determined the feasibility of measuring
caspase-3 activity in preoperative biopsies in archive samples of
47 fresh-frozen preoperative biopsies and corresponding
resected rectal tumors. Caspase-3 activity levels in preoperative
biopsies and in tumor samples were highly correlated
(correlation coefficient = 0.56; P < 0.0001, Spearman’s Rho
test). Levels were significantly higher in the tumor specimens
[median, 31.4 pmol AMC/min/mg protein (IQR, 15.1-109.9)]
than in the preoperative biopsies [median, 23.3 pmol AMC/
min/mg protein (IQR, 8.7-48.5); P = 0.002, Wilcoxon signed
rank].
These results indicate that determination of levels of
apoptosis by caspase-3 activity in preoperative biopsies can be
used in predicting level of apoptosis in rectal tumors.
Discussion
Preoperative radiation therapy has shown to be of benefit for
the prevention of local recurrence rates in rectal cancer patients
(11, 12). Long-course preoperative chemoradiotherapy is of
benefit in stage T3/T4 rectal cancer patients, and long-course
preoperative chemoradiation is the standard of care in the
United States (27). However, considering the extensive
morbidity of preoperative radiation therapy (13–15), it is of
great importance to identify patients with a low risk of local
recurrence in which radiation therapy is redundant. With this
intention, the current study was done in patients with stage III
rectal cancer, as these patients are at the highest risk for local
recurrence (12). Our results show that biochemical detection of
caspase-3 levels can be used as a marker to identify patients
with a very high probability for local cure with surgery alone.
To select patients who can be refrained from preoperative
radiation therapy, a marker should provide accurate prediction
of clinical behavior and it must be applicable in a pretreatment
biopsy of the tumor. Several markers for prediction of radiation
therapy efficacy have been suggested in previous studies,
including analysis of Ki-67, BAX, cyclooxygenase-2, survivin,
and M30 staining (17–19, 28–30). As the benefit of radiation
therapy is, at least in part, mediated by the induction of tumor
cell apoptosis and other forms of cell death (20, 31, 32), it is
not surprising that the majority of these markers involve
proapoptotic or antiapoptotic proteins. A recent study evaluat-
ed the predictive value of tumor cell apoptosis as quantified by
immunohistochemical staining of paraffin-embedded tumor
tissue arrays with the M30 antibody in rectal cancer specimens
from the Dutch TME trial (19). In this study, the number of
M30-positive cells showed to be a significant predictor of local
recurrence but with at much lower levels of statistical
significance than we found measuring caspase-3 activity. This
may be due to limited accuracy of quantifying cells by
immunohistochemical staining or the influence of apoptotic
infiltrative cells that were included in measured caspase activity.
Preoperative biopsies may yield a limited number of tumor
cells (16), thus further limiting the use of immunohistochem-
ical markers such as M30 to detect the number of apoptotic
tumor cells to select patients for radiation therapy. By
measuring enzymatic caspase-3 activity, apoptosis can be
determined even before the phenotypic changes of these cells
are clearly detectable. In addition, our study showed that only
10 Ag of tumor-derived protein were necessary for a single
assay, making biochemical detection of caspase-3 activity a
feasible assay to determine apoptotic levels in preoperative
biopsies of rectal tumors.
Caspase-3 activity in the current study was evaluated in
nonirradiated tumors, as several studies have convincingly
showed that radiation therapy– induced apoptosis is not of
prognostic value (17, 19). Evaluation of enzymatic caspase-3
activity as an indicator of apoptotic cell death seemed in this
study an accurate variable for prediction of local recurrences.
Preoperative biopsies are routinely taken for diagnosis in
diseases of the large bowel. For biochemical quantification of
caspase-3 activity, an additional biopsy can be taken and
either processed immediately or freshly frozen for analysis
later.
A highly significant association between caspase-3 activity in
the biopsies and corresponding tumor suggests that determin-
ing levels of caspase-3 activity in pretreatment biopsies can be
used in predicting level of apoptosis in tumors. It must be taken
into account that caspase-3 levels were significantly lower in
adjacent normal tissue and a risk of misinterpretation of
caspase-3 levels can be apparent if a biopsy contains normal
tissue. Caspase-3 activity in the archival biopsies that we studied
was significantly lower than in the corresponding resected
tumor specimens, suggesting an effect of tumor resection on
apoptosis.
One of the factors predictive for local recurrences in rectal
cancer is a positive circumferential resection margin (33), and
short-term preoperative radiation therapy is of limited effect in
patients with a circumferential margin of V1 mm (21). In the
nonirradiated stage III rectal cancer patients evaluated in this
study, the presence of positive resection margins was not a
prognostic factor. Apparently, other factors are of more
importance in this subset of stage III patients. A possible
explanation could be lymphatic spread beyond the surgical
resection. In this study, a positive resection margin was
associated with low caspase-3 activity in the residual tumor
specimens, suggesting that tumors with low levels of apoptosis
do not have a clear invasive front and, therefore, are difficult to
resect completely. Several clinical and pathologic factors as
Table 3. Results of multivariate Cox regression
analysis of local recurrence among 117
nonirradiated stage III rectal cancer patients
Variable Association with local recurrence
(Cox regression analysis)
HR (95% CI) P
Caspase-3 activity 0.009
> Median 1
V Median 7.5 (1.7-34.1)
Type of resection 0.87
Abdominoperineal 1
Low anterior 1.12 (0.3-4.6)
Distance of tumor from anal verge (cm) 0.36
10.1-15 1
5.1-10 2.3 (0.3-16.3)
V5 3.2 (0.7-15.3)
T status 0.11
T1-T2 1
T3 4.4 (0.2-72.1)
T4 5.7 (0.7-39.7)
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lymph node metastases and tumors located within 10 cm from
anal verge are predictors of local recurrence (12, 24, 25, 33). It
has already been shown that magnetic resonance imaging can
improve the selection of patients who may have a positive
circumferential margin (34). Preoperative detection of positive
lymph nodes by magnetic resonance imaging in combination
with ultrasmall particles of iron oxide is currently being
reviewed and tested in clinical studies (34, 35). This is likely
to result in a better preoperative staging of patients and this will
enable accurate identification of stage III patients, which are
candidates for preoperative radiation therapy. To establish a
caspase-3 activity level that can be generalized to a broader
population of rectal cancer patients, we are currently prospec-
tively collecting preoperative rectal cancer biopsies for analyses
of caspase-3 activity. Selection of patients who will not benefit
from preoperative radiation therapy by determination of
caspase-3 activity will drastically further decrease the number
of patients who receive unnecessary preoperative radiation
therapy.
In conclusion, the present study shows that caspase-3 activity
is an important denominator of local recurrence in rectal cancer
and suggests that identification of patients with a low risk of
recurrence can be achieved by caspase-3 measurement in
preoperative biopsies. If an independent study can confirm
our results, determination of caspase-3 levels should be added
to other selection criteria to select rectal cancer patients in
whom radiation therapy is redundant.
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